Semaglutide, a glucagon like peptide-one (GLP-1) receptor agonist, is obtainable as monotherapy in both subcutaneous together with oral dosage sort (initially approved oral GLP-one receptor agonist). It's been authorised to be a second line therapy selection for improved glycaemic Handle in sort two diabetes and currently underneath scrutiny for anti-weight https://shulamithf443qcn6.wikijm.com/user